Clene Inc Ordinary Shares CLNN 深 滬
等待開盤 09-09 09:30:00 美东时间
6.63
+0.600
+9.95%
華盛通- 最 高7.10
- 今 開6.10
- 成交量 25.98万股
- 最 低 6.06
- 昨 收 6.03
- 總市值 5955.53万
- 52周最高 7.10
- 市盈率 靜 --
- 換手率 2.89%
- 52周最低 2.2801
- 委 比 -27.27%
- 總股本 898.27万
- 歷史最高 356.40
- 量 比 2.57
- 振 幅 17.25%
- 歷史最低 2.2801
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clene Expands Equity Distribution to Raise Capital
Clene ( ($CLNN) ) has issued an announcement. On April 28, 2025, Clene Inc. ent...
09-06 04:49
Clene Inc Announces New Preclinical Data Showing That Its Lead Candidate, CNM-Au8, Improved Cellular Health In A Dopaminergic Neuron Model Of Parkinson's Disease
Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression
09-04 20:38
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
Clene Inc. announced new preclinical data showing CNM-Au8 improved mitochondrial health, reduced inflammation, restored cellular metabolism, and normalized gene expression in Parkinson’s disease (PD) dopaminergic neuron models derived from patients. These findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting, further support CNM-Au8’s potential as a PD treatment. The study also demonstrated CNM-Au8’s favorable s...
09-04 12:30
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Clene Inc. and its subsidiary Clene Nanomedicine Inc. announced they will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025, with a virtual presentation available on September 5. Clene focuses on treating neurodegenerative diseases like ALS and MS through its lead candidate CNM-Au8®, targeting mitochondrial function and reducing oxidative stress. Investors can schedule 1x1 meetings vi...
09-02 12:00
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
08-15 00:08
Clene Q2 EPS $(0.78) Misses $(0.47) Estimate, Sales $27.000K Miss $52.833K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.47) by 64.9 percent. This is a 26.42 percent increase over losses of $(1.06) per share from the same
08-14 20:44
